

Resource Summary Report

Generated by RRID on Aug 4, 2026

American Cancer Society

RRID:SCR_005756

Type: Tool

Proper Citation

American Cancer Society (RRID:SCR_005756)

Resource Information

URL: <http://www.cancer.org/>

Proper Citation: American Cancer Society (RRID:SCR_005756)

Description: The American Cancer Society is the nationwide, community-based, voluntary health organization dedicated to eliminating cancer as a major health problem by preventing cancer, saving lives, and diminishing suffering from cancer, through research, education, advocacy, and service. Together with our millions of supporters, the American Cancer Society (ACS) saves lives and creates a world with less cancer and more birthdays by helping people stay well, helping people get well, by finding cures, and by fighting back. Headquartered in Atlanta, Georgia, the ACS has 12 chartered Divisions, more than 900 local offices nationwide, and a presence in more than 5,100 communities.

Abbreviations: ACS

Synonyms: American Cancer Society - The Official Sponsor of Birthdays

Resource Type: non profit organization

Keywords: cancer, breast cancer, colon, lung, prostate, skin, breast

Related Condition: Cancer

Resource Name: American Cancer Society

Resource ID: SCR_005756

Alternate IDs: grid.422418.9, Wikidata: Q463665, nlx_149219, ISNI: 0000 0004 0371 6485, Crossref funder ID: 100000048

Alternate URLs: <https://ror.org/02e463172>

Record Creation Time: 20220129T080232+0000

Record Last Update: 20260801T190302+0000

Ratings and Alerts

No rating or validation information has been found for American Cancer Society.

No alerts have been found for American Cancer Society.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 476 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Poei D, et al. (2025) Real-World Incidence of Anaplastic Lymphoma Kinase Alterations in Hispanics with Non-Small Cell Lung Cancer at a Large Academic Institution in Los Angeles. *Cancer research communications*, 5(2), 277.

Heckman CJ, et al. (2025) Digital Skin Cancer Risk Reduction Interventions for Young Adults: Findings from a Hybrid Type-II Effectiveness-Implementation Trial. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*, 34(6), 962.

Trouth A, et al. (2025) The length of the G1 phase is an essential determinant of H3K27me3 landscapes across diverse cell types. *PLoS biology*, 23(4), e3003119.

Patton ME, et al. (2025) Sex differences in bile acid homeostasis and excretion underlie the disparity in liver cancer incidence between males and females. *eLife*, 13.

Stenzl A, et al. (2025) Evaluation of ChatGPT as a Reliable Source of Medical Information on Prostate Cancer for Patients: Global Comparative Survey of Medical Oncologists and Urologists. *Urology practice*, 12(2), 229.

Wu C, et al. (2025) Pharmaceutical Company's Choices of Indication for the First Clinical Projects in Oncological Drug Development in the United States. *Therapeutic innovation & regulatory science*, 59(1), 9.

Li Q, et al. (2025) The PRL2 phosphatase up-regulates miR-21 through activation of the JAK2/STAT3 pathway to down-regulate the PTEN tumor suppressor. *The Biochemical journal*, 482(7), 341.

Spuur K, et al. (2025) Suitability of ChatGPT as a Source of Patient Information for Screening Mammography. *Health promotion practice*, 26(4), 746.

Armand J, et al. (2025) Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer. *eLife*, 14.

Sandúa A, et al. (2025) Utility of PSA in extracellular vesicles as a follow-up biomarker in prostate cancer. *Advances in laboratory medicine*, 6(4), 442.

Inagaki T, et al. (2025) KSHV TR deletion episomes uncover enhancer-promoter dynamics in gene regulation. *PLoS pathogens*, 21(12), e1013061.

Kaur A, et al. (2025) Machine learning approach for optimizing usability of healthcare websites. *Scientific reports*, 15(1), 14450.

Sandúa A, et al. (2025) [Not Available]. *Advances in laboratory medicine*, 6(4), 450.

Kortleve D, et al. (2024) TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer. *Cancer discovery*, 14(12), 2450.

Yanagawa T, et al. (2024) Random Threshold Model: A Low-Dose Radiation-Induced Risk Assessment Approach Considering Individual Susceptibility to Cancer. *Dose-response : a publication of International Hormesis Society*, 22(4), 15593258241298553.

Lim B, et al. (2024) Phosphorylation of the DNA damage repair factor 53BP1 by ATM kinase controls neurodevelopmental programs in cortical brain organoids. *PLoS biology*, 22(9), e3002760.

Giacomini A, et al. (2024) The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma. *Journal of experimental & clinical cancer research : CR*, 43(1), 294.

Rathmann W, et al. (2024) Comment on Hsieh et al. COVID-19 Vaccination Prior to SARS-CoV-2 Infection Reduced Risk of Subsequent Diabetes Mellitus: A Real-World Investigation Using U.S. Electronic Health Records. *Diabetes Care* 2023;46:2193-2200. *Diabetes care*, 47(11), e92.

King ES, et al. (2024) Diverse mutant selection windows shape spatial heterogeneity in evolving populations. *PLoS computational biology*, 20(2), e1011878.

Ye?ilda? A, et al. (2024) Anticarcinogenic Effects of Gold Nanoparticles and Metformin Against MCF-7 and A549 Cells. *Biological trace element research*, 202(10), 4494.